These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8044157)

  • 1. Quality of life among patients post-myocardial infarction at baseline in the Survival and Ventricular Enlargement (SAVE) trial.
    Gorkin L; Follick MJ; Geltman E; Hamm P; Sollano J; Sylvia S; Jacobson K; Jacobson MJ; Cochrane BS; Sussex B
    Qual Life Res; 1994 Apr; 3(2):111-9. PubMed ID: 8044157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
    Rutherford JD; Pfeffer MA; Moyé LA; Davis BR; Flaker GC; Kowey PR; Lamas GA; Miller HS; Packer M; Rouleau JL
    Circulation; 1994 Oct; 90(4):1731-8. PubMed ID: 7923656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.
    St John Sutton M; Pfeffer MA; Plappert T; Rouleau JL; Moyé LA; Dagenais GR; Lamas GA; Klein M; Sussex B; Goldman S
    Circulation; 1994 Jan; 89(1):68-75. PubMed ID: 8281697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
    Pfeffer MA
    Herz; 1993 Dec; 18 Suppl 1():430-5. PubMed ID: 8125423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.
    Lamas GA; Flaker GC; Mitchell G; Smith SC; Gersh BJ; Wun CC; Moyé L; Rouleau JL; Rutherford JD; Pfeffer MA
    Circulation; 1995 Sep; 92(5):1101-9. PubMed ID: 7648653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators.
    Moyé LA; Pfeffer MA; Braunwald E
    Am J Cardiol; 1991 Nov; 68(14):70D-79D. PubMed ID: 1836100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.
    Plosker GL; McTavish D
    Drugs Aging; 1995 Sep; 7(3):226-53. PubMed ID: 8535052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study.
    Moyé LA; Pfeffer MA; Wun CC; Davis BR; Geltman E; Hayes D; Farnham DJ; Randall OS; Dinh H; Arnold JM
    Eur Heart J; 1994 May; 15 Suppl B():2-8; discussion 26-30. PubMed ID: 8076658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.
    Young JB
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):89-102. PubMed ID: 7786840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
    Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
    Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.
    St John Sutton M; Pfeffer MA; Moye L; Plappert T; Rouleau JL; Lamas G; Rouleau J; Parker JO; Arnold MO; Sussex B; Braunwald E
    Circulation; 1997 Nov; 96(10):3294-9. PubMed ID: 9396419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance.
    Kyriakidis M; Antonopoulos A; Georgiou E; Santas P; Bakirtzis C; Toutouzas P
    Eur Heart J; 1996 Jun; 17(6):864-73. PubMed ID: 8781825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement.
    Pfeffer MA
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):106S-111S. PubMed ID: 7818835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
    Le Pen C; Lévy E; Bonte J
    Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
    Rouleau JL; Packer M; Moyé L; de Champlain J; Bichet D; Klein M; Rouleau JR; Sussex B; Arnold JM; Sestier F
    J Am Coll Cardiol; 1994 Sep; 24(3):583-91. PubMed ID: 7915733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators.
    Pfeffer MA; Moyé LA; Braunwald E; Basta L; Brown EJ; Cuddy TE; Dagenais GR; Flaker GO; Geltman EM; Gersh BJ
    JAMA; 1991 Jul 24-31; 266(4):528-32. PubMed ID: 2061979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.